Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Operating Expenses (2016 - 2025)

Historic Operating Expenses for CorMedix (CRMD) over the last 13 years, with Q3 2025 value amounting to $41.7 million.

  • CorMedix's Operating Expenses rose 19689.94% to $41.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.5 million, marking a year-over-year increase of 6877.12%. This contributed to the annual value of $62.6 million for FY2024, which is 2794.29% up from last year.
  • Per CorMedix's latest filing, its Operating Expenses stood at $41.7 million for Q3 2025, which was up 19689.94% from $18.3 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Operating Expenses ranged from a high of $41.7 million in Q3 2025 and a low of $5.9 million during Q2 2021
  • Moreover, its 5-year median value for Operating Expenses was $10.7 million (2023), whereas its average is $13.0 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 3410.99% in 2021, then soared by 19689.94% in 2025.
  • CorMedix's Operating Expenses (Quarter) stood at $7.8 million in 2021, then grew by 8.09% to $8.4 million in 2022, then grew by 24.34% to $10.5 million in 2023, then surged by 63.35% to $17.1 million in 2024, then soared by 144.09% to $41.7 million in 2025.
  • Its last three reported values are $41.7 million in Q3 2025, $18.3 million for Q2 2025, and $17.4 million during Q1 2025.